Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

Ivan Borrello, medical director of the Myeloma, Bone Marrow Transplant and Cell Therapies Program at Tampa General Hospital’s Cancer Institute, watched as flood waters from Hurricane Helene heaved against a contraption called the AquaFence, which is, as the name suggests, a water-impermeable barrier made of marine-grade laminate and various metals that can withstand storm surges of up to 15 feet above sea level.

October 18, 2024

Vol.50 No.39

By Claire Marie Porter

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids

Hurricane Milton via satellite on Wednesday. Source: NOAA/NESDISSTAR GOES-EastMilton—the second hurricane in as many weeks—ripped through America’s southeast, causing severe flooding, washing away bridges, knocking out power and water supply.

October 11, 2024

Vol.50 No.38

By Claire Marie Porter

Regulatory News

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC

FDA approved Opdivo (nivolumab) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent Opdivo after surgery as adjuvant treatment, for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.

October 04, 2024

Vol.50 No.37

Regulatory News

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

FDA approves Tagrisso for stage 3 EGFR-mutated NSCLC

FDA approved Tagrisso (osimertinib) in the U.S. for treatment of adult patients with unresectable, stage 3 epidermal growth factor receptor-mutated non-small cell lung cancer whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy.

September 27, 2024

Vol.50 No.36

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

YOU MAY BE INTERESTED IN

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

FDA approves Tagrisso for stage 3 EGFR-mutated NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

YOU MAY BE INTERESTED IN

Climate change exacerbates cancer disparitiesAmid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on scheduleHelene knocks out Baxter facility, creating shortage of IV fluids

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitorsVote may lead to rollback of some indications held by BMS and Merck

FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitorsVote applies across drugs and indications

FDA approves Tagrisso for stage 3 EGFR-mutated NSCLC

Never miss an issue!

Login

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications